Production (Stage)
NRx Pharmaceuticals, Inc.
NRXP
$3.27
$0.3311.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.81% | -5.00% | -28.11% | -36.62% | -44.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.73% | -28.58% | -38.08% | -36.10% | -36.55% |
| Operating Income | 27.73% | 28.58% | 38.08% | 36.10% | 36.55% |
| Income Before Tax | 5.96% | 16.66% | 43.48% | 36.49% | 31.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.96% | 16.66% | 43.48% | 36.49% | 31.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.96% | 16.66% | 43.48% | 36.49% | 31.35% |
| EBIT | 27.73% | 28.58% | 38.08% | 36.10% | 36.55% |
| EBITDA | 27.74% | 28.58% | 38.09% | 36.10% | 36.56% |
| EPS Basic | 38.37% | 42.43% | 57.64% | 51.97% | 43.07% |
| Normalized Basic EPS | 39.19% | 38.94% | 50.90% | 49.10% | 46.86% |
| EPS Diluted | 38.66% | 42.63% | 57.74% | 52.09% | 42.68% |
| Normalized Diluted EPS | 39.19% | 38.94% | 50.90% | 49.10% | 46.86% |
| Average Basic Shares Outstanding | 54.60% | 40.88% | 33.33% | 30.71% | 22.36% |
| Average Diluted Shares Outstanding | 54.60% | 40.88% | 33.33% | 30.71% | 22.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |